Clinical trials: CART Cells
Leukemia, Acute, Leukemia, Lymphoblastic
The SMART CART Study: Health Information Technology
This study evaluates the feasibility of using two information technology tools in patients undergoing Chimeric Antigen Receptor T-cell (CART) therapy and other Cytokine Release Syndrome (CRS)-eliciting treatments such as CD123…
- Trial name
- NCT04051216
- Testing
- Education information system, Activity monitor, Interview
- Where
- United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Multiple Sclerosis, Myasthenia Gravis
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or…
- Trial name
- NCT06220201
- Testing
- CC-97540, Fludarabine, Cyclophosphamide
- Where
- 34 sites in United States, Belgium and 4 more
- Volunteers
- 120 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Relapsed/Refractory Multiple Myeloma
Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease
The study proposed here intends to evaluate the safety and efficacy of escalating doses of autologous PMCC-COE-KMA CAR T-cells administered to patients with relapsed/refractory multiple myeloma that expresses the KMA.
- Trial name
- KOALA (NCT07541391)
- Testing
- PMCC-COE-KMA
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Patients With Diffuse Large B-cell Lymphoma Treated With CART-cells
Quality Of Life and Drug Use in Patients With CAR-T Cells
CAR-T cells are a major therapeutic innovation in the management of patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) in 3rd line or more.
- Trial name
- QOLD CAR-T (NCT04914091)
- Testing
- Semi-structured interviews and self-administered questionnaires
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Hospices Civils de Lyon
HCC
Phase I Study of OriC902 in Treatment of Advanced HCC
This is a Phase I clinical study evaluating the safety, pharmacokinetics, and initial efficacy of a GPC3-targeted chimeric antigen receptor autologous T cell injection (OriC902) in GPC3-positive advanced hepatocellular carcinoma…
- Trial name
- NCT06891742
- Testing
- OriC902
- Where
- 2 sites in China
- Volunteers
- 44 people
- Sponsor
- Peking University
Acute Leukemia
Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia
The purpose of this study is to evaluate the safety and efficacy of chimeric antigen receptor 19 (CD19-CAR-T2 Cells) infusions in patients with chemotherapy resistant or refractory CD19+ acute Leukemia.
- Trial name
- NCT02822326
- Testing
- CD19-CAR-T2 Cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangdong Provincial People's Hospital
Leukemia, B-Cell, Lymphoma, B-Cell
Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
This single arm, open-label, multi-center clinical trial is studying CD19 targeted chimeric antigen receptor T cells therapy in treating patients with CD19 positive malignant B-cell derived leukemia and lymphoma that is relapsed…
- Trial name
- NCT02813837
- Testing
- CD19CART
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Innovative Cellular Therapeutics Co., Ltd.
Safety, Effective
Anti-CD19 CAR-T Cell Therapy in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
This is an open, Phase I, investigator-initiated study (IIT) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-04 in patients with moderate or severe active SLE.
- Trial name
- NCT06310811
- Testing
- RD06-04 Cells injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Pancreatic Cancer
Autologous CARTmeso/19 Against Pancreatic Cancer
Pancreatic cancer patients receive chimeric antigen receptor (CAR) T cells against mesothelin (CARTmeso) or CD19 (CART19) cells administered at 3 days via pancreatic artery infusion or i.v.
- Trial name
- NCT03497819
- Testing
- CARTmeso CART19
- Where
- China
- Volunteers
- 10 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Metastatic Castration-resistant Prostate Cancer
A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer
Multi-center, open-label, Phase 1 study of the safety, tolerability and feasibility of dosing patients harboring metastatic castration resistant prostate cancer (mCRPC) with genetically modified autologous T cells…
- Trial name
- NCT04227275
- Testing
- CART-PSMA-TGFβRDN, Cyclophosphamide, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 16 people
- Sponsor
- Tceleron Therapeutics, Inc.
Multiple Myeloma
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.
- Trial name
- iMMagine-1 (NCT05396885)
- Testing
- anitocabtagene-autoleucel
- Where
- 18 sites in United States
- Volunteers
- 136 people
- Sponsor
- Kite, A Gilead Company
Liver Metastases
A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
The purpose of this study is to collect the data on the safety and potential effectiveness of intra-tumor injection of MG7-CART cells under ultrasound guidance in patients with liver metastases expressing MG7 positively.
- Trial name
- NCT02862704
- Testing
- MG7-CART
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xijing Hospital
Solid Tumor
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
The proposed clinical study is a Phase 1/2a trial to investigate the safety, tolerability, pharmacokinetics and clinical activity of anti-HLA-G CAR-T cells IVS-3001 administered to subjects with previously treated, locally…
- Trial name
- NCT05672459
- Testing
- Single Injection of IVS-3001- Anti - HLA-G CAR-T cells, Fludarabine phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Myasthenia Gravis, Generalized
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis
- Trial name
- NCT04146051
- Testing
- Descartes-08
- Where
- 15 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Cartesian Therapeutics
Acute Lymphoblastic Leukemia ALL
Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the…
- Trial name
- NCT06608342
- Testing
- Autologous hematopoietic stem cell transplantation combined with CD19-CART
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Sclerosis, CAR T Cell Therapy
MB-CART2019.1 in Refractory Multiple Sclerosis
The goal of this trial is to assess the feasibility, safety and preliminary efficacy of MB-CART2019.1 in patients with active refractory primary and secondary progressive MS.
- Trial name
- NCT07178431
- Testing
- MB-CART2019.1
- Where
- Germany
- Volunteers
- 26 people
- Sponsor
- Miltenyi Biomedicine GmbH
Autoimmune Disease
The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD
This is an open label, Multi-center，dose-escalation study in up to 18 participants with refractory NMOSD. This study aims to evaluate the safety and efficacy of universal CAR-T Cells targeting BCMA in the Treatment of refractory…
- Trial name
- NCT06633042
- Testing
- Universal BCMA-CD19 CART
- Volunteers
- 18 people
- Sponsor
- Bioray Laboratories
Multiple Myeloma
A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities
This is a single-arm, open-label study to evaluate the efficacy and safety of VRD(Bortezomib, Lenalidomide and Dexamethasone)-based regimen combined with CART-ASCT-CART2 in patients with newly diagnosed multiple myeloma with p53…
- Trial name
- NCT05850286
- Testing
- anti-BCMA CAR-T, VRD-based Regimen
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric…
- Trial name
- NCT04544592
- Testing
- CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Colorado, Denver